$RVXCF share an idea or ask a question..... I'm
Post# of 98042
I'm very bullish on this little Canadian Biotech which is now about 2 years in to a Phase III trial called BETonMACE which is looking to prove that Apabetalone (the company's lead compound) will signifcantly reduce the incedence of Major Adverse Cardiac Events (MACE) in patients with Diabetes Mellitus. Earlier Phase II trials showed a 77% reduction in MACE among this group.
Here's the IHangout board for Resverlogix:
https://investorshangout.com/Resverlogix-Corp-RVXCF-66357/
Below the radar right now, but if they succeed it won't be for long...be one of the first to chime in.